Digest Network Come funziona
Network
/
Società
Ep
Non verificato

Epicrispr Biotechnologies

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
08/01/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Web e Social Network
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
05/08/2025
Sanità
Scienza
Farmaceutica
Vetrine/Shopping
Biotecnologia
Infanzia
Medicina - Varie
Igiene alimentare
Salute
Industria
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
12/05/2025
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
05/05/2025
Eventi
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
23/04/2025
Industria
Attrezzature medico-sanitarie
Salute
Tecnica
Biotecnologia
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
03/04/2025
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0
26/03/2025
Scienza
Sanità
Associazioni/Professionisti
Farmaceutica
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
Fonte
Epicrispr Biotechnologies
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0